Cyclosporine as Therapy for Traumatic Brain Injury.

ABSTRACT: Drug development in traumatic brain injury (TBI) has been impeded by the complexity and heterogeneity of the disease pathology, as well as limited understanding of the secondary injury cascade that follows the initial trauma. As a result, patients with TBI have an unmet need for effective pharmacological therapies. One promising drug candidate is cyclosporine, a polypeptide traditionally used to achieve immunosuppression in transplant recipients. Cyclosporine inhibits mitochondrial permeability transition, thereby reducing secondary brain injury, and has shown neuroprotective effects in multiple preclinical models of TBI. Moreover, the cyclosporine formulation NeuroSTAT^® displayed positive effects on injury biomarker levels in patients with severe TBI enrolled in the Phase Ib/II

SUBMITTER: Hansson MJ 

PROVIDER: S-EPMC10684836 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature